Market Access

Erez Israeli explains how Dr. Reddy's approached commercial readiness for its generic semaglutide launch in Canada and what vertical integration in peptide manufacturing means for the GLP-1 market.

Cencora will support US distribution of Kite's Yescarta and Tecartus, reducing administrative burdens and expanding CAR T-cell therapy access at authorized treatment centers.

Cameron Olig explains how transparency and direct access models can help pharma close the gap between drug pricing, distribution and the patient.

Early launch planning, streamlined patient access, and measured AI adoption help specialty therapy programs accelerate treatment and sustain success.

The PBM’s updated commercial formularies reflect negotiated pricing progress with manufacturers.

As specialty drug launches grow, pharma leaders are rethinking patient access as a core commercialization strategy to reduce delays and improve therapy starts.

Generic drug shortages may seem sudden, but they stem from ongoing pressures in manufacturing, pricing, and global supply chains, especially in hospitals.

Cash pay is re-emerging as biopharma brands rethink insurance barriers, patient access, and affordability in a fragmented payer market.

Tommy Bramley explains how real-world evidence is reshaping how specialty pharma demonstrates value — from trial design to payer negotiations and patient outcomes.

High copays, restrictive networks, and travel distances leave many rural Americans facing steep barriers to prescription access.

Rahul Mittal explains how execution infrastructure can help generics manufacturers improve hospital access, reduce delays, and strengthen coordination.

The expansion of TrumpRx will increase price transparency and purchase options of generic drugs for cash-paying patients.

Jeremy Richardson explains how direct-to-patient models increase drug pricing transparency and demonstrate value.

For drugs already on the market, there may be little companies can do to limit business impact; however, for new development drugs, there are some critical considerations.

Angelini Pharma is acquiring Catalyst Pharmaceuticals in a $4.1 billion transaction that expands its presence in the US rare disease market and adds a portfolio of neuromuscular and neurological therapies.

As specialty drug costs rise, employers and sponsors must balance alternative funding programs and in-benefit optimization to achieve sustainable savings without disrupting patient care.

GoodRx now offers oral Ozempic as an alternative to injectable GLP-1 therapies.

As cell and gene therapies move beyond ultra-rare disease indications into broader patient populations, the commercialization infrastructure built around them is due for a fundamental redesign.

Will Shrank, MD, evaluates opportunities and challenges in specialty pharma over the next few years.

At Asembia AXS26, Dee Chaudhary broke down how shifting US drug pricing policy is tightening payer controls and changing pharmaceutical pricing and forecasting.

Avalere Health analysts map the converging pressures reshaping the drug pricing and distribution landscape ahead of November.

TailorMed broadens patient support beyond copay help, adding five modules that link access, affordability and adherence across specialty medications.

Fran Gregory, VP of Emerging Therapies at Cardinal Health, discusses key findings from the company's 2026 Advanced Therapy Report.

Charley Maxwell explains why Annex 21 is not just a regulatory hurdle, but a key commercial risk point.